Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous HPV6 E6 and E7 peptide-loaded dendritic cell
- Development stage
- Phase 1
- Lead developer
- National Cancer Institute
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
This is an autologous cellular immunotherapy consisting of a patient's own dendritic cells that have been loaded ex vivo with peptides derived from the E6 and E7 oncoproteins of the Human Papillomavirus type 6 (HPV6). Dendritic cells are professional antigen-presenting cells; when pulsed with these specific viral antigens and re-administered to the patient, they are intended to prime and activate cytotoxic T lymphocytes (CTLs) to recognize and destroy HPV6-infected cells. This approach is primarily investigated for the treatment of Recurrent Respiratory Papillomatosis (RRP), a rare disease characterized by the growth of noncancerous tumors in the airway caused by HPV6 or HPV11. The therapy aims to provide a targeted immune response to eliminate the underlying viral infection and reduce the frequency of surgical interventions required for tumor removal.
- Other names
- HPV6 E6/E7 peptide-pulsed autologous dendritic cell vaccineautologous dendritic cells pulsed with HPV 6 E6 and E7 peptides
02
Targets
Human papillomavirus type 6 E6 protein-derived peptide-MHC complexpMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on autologous HPV6 E6 and E7 peptide-loaded dendritic cell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous HPV6 E6 and E7 peptide-loaded dendritic cell.